IL‐7 germline variant: setting the stage for immune‐related adverse events

Treatment with immune checkpoint inhibitors (ICIs) is frequently associated with immune‐related adverse events (irAEs). A new study identified an interleukin 7 (IL‐7) allelic variant—rs16906115—as a major risk factor for the development of ICI‐associated irAEs. This association is of great significa...

Descripción completa

Detalles Bibliográficos
Autores principales: Issaoui, Hussein, Ricci, Jean‐Ehrland
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Commentaries
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9980302/
https://www.ncbi.nlm.nih.gov/pubmed/36748568
http://dx.doi.org/10.1002/1878-0261.13392
_version_ 1784899886093697024
author Issaoui, Hussein
Ricci, Jean‐Ehrland
author_facet Issaoui, Hussein
Ricci, Jean‐Ehrland
author_sort Issaoui, Hussein
collection PubMed
description Treatment with immune checkpoint inhibitors (ICIs) is frequently associated with immune‐related adverse events (irAEs). A new study identified an interleukin 7 (IL‐7) allelic variant—rs16906115—as a major risk factor for the development of ICI‐associated irAEs. This association is of great significance as it indicates that germline genetic variants influence the occurrence of irAEs, thus opening a new avenue for identifying high‐risk patients to enable better management of ICI therapy and associated irAEs.
format Online
Article
Text
id pubmed-9980302
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-99803022023-03-03 IL‐7 germline variant: setting the stage for immune‐related adverse events Issaoui, Hussein Ricci, Jean‐Ehrland Mol Oncol Commentaries Treatment with immune checkpoint inhibitors (ICIs) is frequently associated with immune‐related adverse events (irAEs). A new study identified an interleukin 7 (IL‐7) allelic variant—rs16906115—as a major risk factor for the development of ICI‐associated irAEs. This association is of great significance as it indicates that germline genetic variants influence the occurrence of irAEs, thus opening a new avenue for identifying high‐risk patients to enable better management of ICI therapy and associated irAEs. John Wiley and Sons Inc. 2023-02-24 /pmc/articles/PMC9980302/ /pubmed/36748568 http://dx.doi.org/10.1002/1878-0261.13392 Text en © 2023 The Authors. Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Commentaries
Issaoui, Hussein
Ricci, Jean‐Ehrland
IL‐7 germline variant: setting the stage for immune‐related adverse events
title IL‐7 germline variant: setting the stage for immune‐related adverse events
title_full IL‐7 germline variant: setting the stage for immune‐related adverse events
title_fullStr IL‐7 germline variant: setting the stage for immune‐related adverse events
title_full_unstemmed IL‐7 germline variant: setting the stage for immune‐related adverse events
title_short IL‐7 germline variant: setting the stage for immune‐related adverse events
title_sort il‐7 germline variant: setting the stage for immune‐related adverse events
topic Commentaries
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9980302/
https://www.ncbi.nlm.nih.gov/pubmed/36748568
http://dx.doi.org/10.1002/1878-0261.13392
work_keys_str_mv AT issaouihussein il7germlinevariantsettingthestageforimmunerelatedadverseevents
AT riccijeanehrland il7germlinevariantsettingthestageforimmunerelatedadverseevents

Ejemplares similares